Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
June 18, 2010 09:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
June 17, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards' CEO to Present at Needham Healthcare Conference
June 03, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
June 01, 2010 08:31 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Stockholders' Equity Non-Compliance
May 24, 2010 08:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - May 24, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics,...
Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
May 21, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - May 21, 2010) - Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...
Marshall Edwards Appoints CEO as a New Director
May 06, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - May 6, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635
April 29, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards Appoints New President and CEO
April 26, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Receives Notice of Compliance With Nasdaq Continued Listing Requirements
April 20, 2010 09:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - April 20, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today...